TLR3 and Alzheimer disease: In view of the existing research showing that early inflammation is beneficial to the phagocytosis and clearance of Aβ, we administered the TLR3 agonist in AD mice starting from 4 months of age and continuing to 9 months of age to investigate the role of the early activation of TLR3 in the pathological process of AD.